NADAC acquisition cost data for SPIRONOLACTONE 100 MG TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00378043701 | $0.1838 | 2022-12-21 | Rx |
| 16714008601 | $0.1838 | 2022-12-21 | Rx |
| 16714008602 | $0.1838 | 2022-12-21 | Rx |
| 16714008603 | $0.1838 | 2022-12-21 | Rx |
| 16714008604 | $0.1838 | 2022-12-21 | Rx |
| 16729022701 | $0.1838 | 2022-12-21 | Rx |
| 16729022716 | $0.1838 | 2022-12-21 | Rx |
| 51079098001 | $0.1838 | 2022-12-21 | Rx |
| 51079098008 | $0.1838 | 2022-12-21 | Rx |
| 53489032901 | $0.1838 | 2022-12-21 | Rx |
Generic: Spironolactone | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $79.5M | 6,322,254 | 1,526,963 | $0.1988 |
| 2020 | $84.1M | 6,489,414 | 1,580,002 | $0.1959 |
| 2021 | $88.1M | 6,677,567 | 1,709,682 | $0.1961 |
| 2022 | $93.7M | 7,134,262 | 1,857,720 | $0.1941 |
| 2023 | $101.8M | 7,955,547 | 2,081,937 | $0.1903 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $7.9M | 557,519 | 161,858 |
| Texas | $6.9M | 503,335 | 146,443 |
| Florida | $6.5M | 503,471 | 151,614 |
| New York | $5.3M | 429,393 | 113,860 |
| Ohio | $5.1M | 415,952 | 106,915 |
| Pennsylvania | $4.6M | 386,814 | 94,738 |
| Illinois | $3.9M | 329,046 | 90,149 |
| Michigan | $3.8M | 270,367 | 75,197 |
| North Carolina | $3.7M | 316,769 | 84,764 |
| Tennessee | $3.1M | 233,061 | 64,777 |
| Georgia | $3.0M | 250,750 | 68,613 |
| Missouri | $2.9M | 239,850 | 60,696 |
| Indiana | $2.8M | 218,273 | 57,807 |
| Wisconsin | $2.5M | 184,350 | 48,711 |
| Massachusetts | $2.3M | 173,009 | 46,233 |
| Washington | $2.3M | 164,455 | 45,521 |
| Virginia | $2.2M | 184,169 | 52,630 |
| New Jersey | $2.0M | 149,144 | 42,799 |
| Minnesota | $2.0M | 140,649 | 37,040 |
| Alabama | $2.0M | 141,457 | 40,606 |
| Kentucky | $1.9M | 157,673 | 41,004 |
| South Carolina | $1.9M | 154,343 | 43,973 |
| Arizona | $1.8M | 130,449 | 40,645 |
| Colorado | $1.7M | 113,971 | 32,751 |
| Oregon | $1.5M | 106,329 | 30,464 |
| Louisiana | $1.4M | 129,551 | 34,181 |
| Oklahoma | $1.3M | 95,015 | 25,448 |
| Maryland | $1.2M | 93,628 | 28,398 |
| Iowa | $1.2M | 114,175 | 26,821 |
| Connecticut | $1.2M | 87,325 | 24,268 |
| Arkansas | $1.2M | 96,325 | 23,437 |
| Mississippi | $1.2M | 106,105 | 27,214 |
| Kansas | $1.1M | 90,136 | 22,592 |
| Utah | $899.4K | 58,121 | 16,964 |
| Puerto Rico | $803.2K | 89,324 | 20,253 |
| Nebraska | $716.0K | 61,719 | 14,304 |
| West Virginia | $669.8K | 57,765 | 15,846 |
| New Mexico | $643.1K | 41,626 | 12,520 |
| Idaho | $640.5K | 52,019 | 14,254 |
| Nevada | $614.3K | 49,300 | 16,070 |
| Maine | $481.9K | 32,199 | 9,342 |
| New Hampshire | $450.7K | 31,042 | 8,894 |
| Montana | $410.8K | 36,308 | 9,121 |
| Rhode Island | $345.5K | 27,881 | 7,376 |
| South Dakota | $338.0K | 32,938 | 7,810 |
| North Dakota | $315.0K | 25,882 | 6,329 |
| Delaware | $250.0K | 19,598 | 5,893 |
| Vermont | $225.7K | 14,030 | 3,708 |
| Hawaii | $189.2K | 14,721 | 4,825 |
| Wyoming | $179.1K | 13,170 | 3,605 |
| Alaska | $172.5K | 13,358 | 3,668 |
| District of Columbia | $172.3K | 11,973 | 4,203 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.